Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)
Muscular Dystrophies
About this trial
This is an interventional treatment trial for Muscular Dystrophies focused on measuring limb girdle muscular dystrophy type 2D, alpha-sarcoglycanopathy, LGMD, LGMD2D, gene therapy, gene transfer, muscular dystrophy, SGCA, sarcoglycan, limb girdle, adeno-associated virus, AAV, AAV1
Eligibility Criteria
Inclusion Criteria:
- Six LGMD2D subjects ages 5 and older based on the clinical degree of involvement (impaired muscle function/weakness, sufficient muscle preservation)
- Preservation of EDB muscle or another muscle if judged more favorable because of adequate muscle mass for gene transfer
- Males and females of any ethnic group
- Established mutations of an -SG gene on both alleles
- Ability to cooperate for testing
- Sexually active patients must be willing to practice a reliable method of contraception during the study
Exclusion Criteria:
- Active viral infection (symptoms listed in section 9.0 of the protocol)
- LGMD2D subjects without weakness or functional loss
- Cardiomyopathy based on clinical exam and ECHO with ejection fraction less than 40%
- HIV infected
- Hepatitis A, B, or C infected
- Autoimmune diseases and immunosuppressive drugs (other than pulse methylprednisolone at time of gene transfer)
- Persistent leucopenia or leucocytosis (WBC less than or equal to 3.5 K/cu mm or at least 20.0 K/ cu mm) or neutrophils less than 1.5 K/ cu mm
- Concomitant illness or requirement for chronic drug treatment that in the opinion of the Principal Investigator creates unnecessary risks for gene transfer
- Pregnancy
- Abnormal laboratory values considered clinically significant
- Alcoholism (CAGE questionnaire), and laboratory tests such as GGT and MCV
Sites / Locations
- The Research Institute at Nationwide Children's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
1
2
The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and two to six vector injections will be distributed in the direction of an X. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
The second cohort will receive the same dose of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.